课题基金 / 基金详情

Arthritic Disease and the Hemostatic System

Arthritic Disease and the Hemostatic System
关节炎疾病和止血系统
批准号:
6848874
负责人:
JAY L DEGEN
金额:
$33.9万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-02-01 至 2009-01-31

项目摘要

项目成果

JAY L DEGEN的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本研究计划的长期目标是了解关键止血因素在炎症性关节疾病中的作用。纤维蛋白(原)和纤维蛋白降解产物在关节内的广泛沉积是类风湿性关节炎最显著的特征之一。鉴于纤维蛋白(原)、纤溶酶(原)、纤维蛋白降解产物(FDPs)及其细胞表面受体在炎症反应和组织重塑/修复中都是重要的,止血相关蛋白是炎症性关节疾病的主要决定因素。该项目的目标集中在下列特定假设:1)纤维蛋白(原)和纤溶酶介导的蛋白分解在导致滑膜重塑、血管疙瘩形成、新生血管、软骨破坏和骨侵蚀的炎症过程中起重要作用;2)纤维蛋白原促进不合时宜的炎症和滑膜细胞活动导致进行性关节退变的机制与:i)临时纤维蛋白基质的局部形成,以及ii)纤维蛋白(原)通过特定的整合素受体在局部细胞参与;以及3)凝血酶,这种将纤维蛋白原转化为纤维蛋白的酶,通过纤维蛋白原依赖和纤维蛋白原非依赖的机制促进关节炎症性疾病。这些假说将通过探索纤维蛋白原、纤溶酶原和纤溶酶原激活物中的遗传缺陷和功能障碍对细胞因子驱动的和适应性免疫驱动的关节炎的影响来检验,这些关节炎是由肿瘤坏死因子-α转基因表达(目标1A)或II型胶原免疫(目标1B)引起的。白细胞和血小板整合素受体的纤维蛋白原结合在关节炎中的特殊重要性将通过对表达缺乏α-M-β-2或α-IIb-β-3整合素结合基序的突变形式的小鼠的关节炎的比较研究来确定(目标2)。同样,在药物和/或基因阻断凝血酶活性的小鼠身上,将确定局部凝血酶介导的纤维蛋白原向不溶性纤维蛋白基质转化在炎性关节疾病发病机制中的重要性(目标3)。建议的研究将提供更详细的了解止血因素在不同病因的关节炎发病机制中的作用,并最终可能阐明治疗关节疾病的新的治疗策略。
英文摘要
DESCRIPTION (provided by applicant): The long-term goal of this research program is to understand the role of key hemostatic factors in inflammatory joint disease. The widespread deposition of fibrin (ogen) and fibrin degradation products within joints is one of the most conspicuous features of rheumatoid arthritis. Given that fibrin (ogen), plasmin(ogen), fibrin degradation products (FDPs), and their cell surface receptors have been shown to be important in both the inflammatory response and tissue remodeling/repair, hemostasis-related proteins are prime candidates to be critical determinants of inflammatory joint disease. The aims of this project center on the following specific hypotheses: 1) fibrin (ogen) and plasmin-mediated proteolysis are important in the inflammatory processes leading to the synovial remodeling, pannus formation, neovascularization, cartilage destruction and bone erosion; 2) the mechanism by which fibrinogen contributes to the inopportune inflammatory and synovial cell activity leading progressive joint degeneration is coupled to: i) the local formation of provisional fibrin matrices, and ii) the local cellular engagement of fibrin(ogen) through specific integrin receptors; and 3) thrombin, the enzyme that proteolytically converts fibrinogen to fibrin, contributes to inflammatory joint disease through both fibrinogen-dependent and fibrinogen-independent mechanisms. These hypotheses will be tested by exploring the impact of genetic deficits and functional disorders in fibrinogen, plasminogen, and plasminogen activators on cytokine-driven and adaptive immunity-driven arthritis induced by either TNF-alpha transgene expression (Aim 1A) or immunization with type II collagen (Aim 1B). The specific importance of fibrinogen engagement of leukocyte and platelet integrin receptors in arthritis will be defined by comparative studies of arthritis in mice expressing mutant forms of fibrinogen lacking either the alpha-M-Beta-2 or alpha-IIb-beta-3 integrin binding motifs (Aim 2). Similarly, the importance of local thrombin-mediated conversion of fibrinogen to insoluble fibrin matrices in the pathogenesis of inflammatory joint disease will be defined in mice where thrombin activity is pharmacologically and/or genetically blocked (Aim 3). The proposed studies will provide a more detailed understanding of the role of hemostatic factors in the pathogenesis of arthritic disease with distinct etiologies, and could ultimately illuminate new therapeutic strategies for treating joint disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Hemostatic factors and sickle cell disease
Hemostatic factors and sickle cell disease
Hemostatic factors and sickle cell disease
FASEB SRC on Protease in Hemostasis and Vascular Biology
海外基金